Clinical Trials
9 trialsNCT00101179 2019-10-18
MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT01383447 2017-08-08
Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00462605 2017-07-18
MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00313586 2017-02-02
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01132573 2014-07-17
Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT01159301 2013-09-19
Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00098891 2013-01-24
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Completed
NCT00020579 2012-03-15
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00015925 2010-03-10
MS-275 in Treating Patients With Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed